A 2025 phase II trial of ziftomenib (menin inhibitor) + gilteritinib in NPM1/FLT3 co-mutated AML reported a 60% complete remission with hematologic recovery (CR/CRh) rate (Crews et al., 2023). The gene discussed is FLT3; the disease is acute myeloid leukemia.